Summary & Overview
HCPCS Level II S0172: Chlorambucil, Oral, 2 mg
HCPCS Level II code S0172 identifies chlorambucil, oral, 2 mg, a cytotoxic alkylating agent used in oncology and hematology. As a drug-specific HCPCS Level II code, S0172 facilitates standardized billing and reimbursement for dispensing or administration of this oral chemotherapy agent across outpatient and pharmacy settings. Nationally, clear coding for antineoplastic agents supports care coordination, benefit determinations, and cost tracking for cancer treatments.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. These payers commonly establish coverage policies and prior authorization requirements for oral oncology agents, making correct HCPCS coding essential for claims processing and patient cost-sharing calculations.
Readers will gain a concise overview of what S0172 represents, the typical sites where services associated with the code occur, and how the code fits into billing workflows. The publication also covers payer coverage landscape, common modifiers associated with HCPCS drug billing, and the clinical context in which chlorambucil may be used. Data not provided in the input for payor-specific rates, taxonomies, ICD-10 pairings, and related procedure codes is noted as unavailable.
Billing Code Overview
HCPCS Level II code S0172 represents Chlorambucil, oral, 2 mg, an oral antineoplastic medication used in the treatment of certain cancers and hematologic malignancies. The code denotes the drug product and strength for billing purposes.
Service Type: Oral chemotherapy medication administration / pharmacy-dispensed drug
Typical Site of Service: Outpatient clinic, physician office, or pharmacy
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a hematologic malignancy such as chronic lymphocytic leukemia (CLL) or low-grade non-Hodgkin lymphoma who receives oral chemotherapy with chlorambucil for cytoreduction or maintenance therapy. The prescribing oncologist or hematologist documents indication, planned dose (commonly 2 mg tablets), treatment schedule, concurrent medications, and baseline labs (CBC, renal and liver function). The workflow includes an office visit for evaluation and informed consent, entry of the prescription into the electronic medical record and specialty pharmacy or outpatient infusion pharmacy, verification of drug coverage and prior authorization if required, medication counseling by a pharmacist or nurse (adverse effects, monitoring, dosing adjustments), and scheduled laboratory monitoring during therapy. Follow-up visits occur with toxicity assessment and dose modification as needed. Typical sites of service are outpatient oncology clinics, physician offices, and outpatient pharmacies dispensing oral chemotherapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard service | Use when no special circumstances apply and service is billed as usual. |
22 | Increased procedural services | Use when additional work or complexity beyond the usual is documented (e.g., extensive physician counseling or management beyond typical for oral chemotherapy initiation). |
23 | Unusual anesthesia | Not typically applicable to oral medication; use only if unusual anesthesia-related circumstances occur. |
52 | Reduced services | Use when service is partially reduced or incomplete (e.g., patient receives partial supply or dose). |
53 | Discontinued procedure | Use if treatment plan was discontinued before delivering the intended service. |
54 | Surgical care only | Generally not applicable to oral chemotherapy; included for completeness when surgical split billing applies. |
55 | Postoperative management only | Not typically applicable to this drug therapy; use only in split global period situations. |
62 | Two surgeons | Rare for oral drug management; use when two providers share responsibility. |
78 | Unplanned return to the OR | Not applicable to oral chemotherapy therapy management. |
80 | Assistant surgeon | Not applicable to oral medication; included when assistant surgeon is involved in related surgical care. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RH0000X | Hematology & Oncology | Oncology and hematology specialists prescribe and manage chlorambucil therapy. |
207RC0000X | Medical Oncology | Medical oncologists manage systemic chemotherapy regimens and monitoring. |
2080P0004X | Hematology | Hematologists provide diagnosis and long-term management for leukemias and lymphomas. |
3336S0206X | Oncology Pharmacy Specialist | Specialty pharmacists provide counseling, dosing verification, and coordination with payors. |
363L00000X | Nurse Practitioner | Advanced practice clinicians in oncology clinics who manage prescriptions and follow-up. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C91.10 | Chronic lymphocytic leukemia of B-cell type, not having achieved remission | Chlorambucil is an oral alkylating agent used historically for cytoreduction in CLL. |
C83.30 | Diffuse large B-cell lymphoma, unspecified, extranodal and solid organ sites | Alkylating agents may be part of regimens or salvage therapy in selected low-intensity settings. |
C85.90 | Non-Hodgkin lymphoma, unspecified, unspecified site | Chlorambucil can be used for indolent non-Hodgkin lymphoma subtypes. |
D61.9 | Aplastic anemia, unspecified | Not an indication for chlorambucil; included as a code to avoid — relevant for monitoring hematologic toxicity if present. |
Z92.21 | Personal history of antineoplastic chemotherapy | Used to document prior exposure to chemotherapy when managing ongoing oral therapy. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
99213 | Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes | Used for routine oncology follow-up visits to assess tolerance, lab results, and medication management for oral chlorambucil. |
99214 | Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes | Used for more complex follow-up visits requiring moderate to high medical decision making or extensive counseling regarding oral chemotherapy. |
99605 | Medication therapy management services for a new patient | Used by pharmacists for initial medication therapy management when initiating oral anticancer therapy. |
36415 | Collection of venous blood by venipuncture | Used for baseline and ongoing laboratory monitoring (CBC, chemistry panels) associated with chlorambucil therapy. |
85025 | Complete blood count (CBC) with automated differential | Common laboratory test performed before and during therapy to monitor for myelosuppression related to chlorambucil. |